HRSV基因組全長約15.2 kb，按照3′到5′順序含有10個基因，分別為3′ -leader-NS1-NS2-N-P-M-SH-G-F-M2-L-trailer-5′，共編碼11種蛋白，包括2個非結(jié)構(gòu)蛋白及9個結(jié)構(gòu)蛋白。

貨號：VVV02802

產(chǎn)品鏈接：http://www.antibodysystem.com/product/13699.html

寄主物種：Human

物種反應(yīng)性：Human respiratory syncytial virus (HRSV)

形式：Liquid

存儲緩沖區(qū)：0.01M PBS, pH 7.4.

濃度：1 mg/ml

純度：>95% by SDS-PAGE.

克隆性：Monoclonal

應(yīng)用：ELISA, In vivo Neutralization

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻：

Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. PMID: 16690930
Gene junction sequences of bovine respiratory syncytial virus. PMID: 1626423

Rhizopus oryzae AM16; a new hyperactive L-asparaginase producer: Semi solid-state production and anticancer activity of the partially purified protein. PMID: 35222999
Genome Sequence Resource of an Avirulent Magnaporthe oryzae Field Strain AM16. PMID: 35728097
A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer. PMID: 25267700
Molecular architecture of bacteriophage T7 capsid. PMID: 6823742
Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the Western Brazilian Amazon. PMID: 34280400
Specificity and efficiency of editing of mismatches involved in the formation of base-substitution mutations by the 3'----5' exonuclease activity of phage T4 DNA polymerase. PMID: 3029763
Optimisation of synthetic vector systems for cancer gene therapy - the role of the excess of cationic dendrimer under physiological conditions. PMID: 24678705
DNA polymerase accuracy and spontaneous mutation rates: frequencies of purine.purine, purine.pyrimidine, and pyrimidine.pyrimidine mismatches during DNA replication. PMID: 6457301
Investigation of the In Vivo Metabolism of Sibirioside A and Angoroside C in Rats by HPLC-ESI-IT-TOF-MSn. PMID: 30347747
Ribosomal proteins L15 and L16 are mere late assembly proteins of the large ribosomal subunit. Analysis of an Escherichia coli mutant lacking L15. PMID: 2204629
Acidiphilamides A-E, Modified Peptides as Autophagy Inhibitors from an Acidophilic Actinobacterium, Streptacidiphilus rugosus. PMID: 30735389
Defined transversion mutations at a specific position in DNA using synthetic oligodeoxyribonucleotides as mutagens. PMID: 158749
呼吸道合胞病毒最早于1955年由美國沃爾特·里德陸軍研究所在患有呼吸道疾病的黑猩猩體內(nèi)發(fā)現(xiàn)，1957年Chanock和Finberg從兒童體內(nèi)分離出，由于其特殊的細胞融合性病變，所以命名為人呼吸道合胞病毒（human respiratory syncytial virus，HRSV）。據(jù)報道，HRSV是世界范圍內(nèi)嬰幼兒下呼吸道感染最重要的病原體之一，有些地區(qū)2歲以內(nèi)的兒童至少發(fā)生過一次感染。近年來，研究發(fā)現(xiàn)HRSV也可引起成年人、老年人以及免疫抑制患者下呼吸道感染。2015年全球范圍內(nèi)由HRSV引起的呼吸道感染人數(shù)約3.31億，導(dǎo)致約320萬5歲以下兒童住院治療，其中約6萬名住院死亡，而老年人住院約33.6萬，住院死亡約為1.4萬，醫(yī)院和社區(qū)每年因HRSV死亡人數(shù)約為10萬～15萬。HRSV占全球兒童急性下呼吸道感染的22%，中國HRSV感染率約為31/1000，占兒童急性下呼吸道感染的18.7%。HRSV觸發(fā)宿主炎癥免疫反應(yīng)，雖然人體對HRSV免疫反應(yīng)尚不完全，但會引起疾病進一步發(fā)展，且HRSV致病機制也尚不完善。HRSV臨床尚無有效疫苗，開發(fā)有效疫苗和單克隆抗體，即是機遇，也是挑戰(zhàn)。隨著呼吸道合胞病毒多種基因型相繼出現(xiàn)，并呈現(xiàn)交替流行以及共流行的現(xiàn)象，基因型的不斷變異、變遷，所造成的疾病程度也有所不同。